Glaxo Gets WHO Approval For Synflorix Pneumococcal Vaccine

Share this

LONDON (Alliance News) - GlaxoSmithKline PLC said Wednesday that the World Health Organization has awarded pre-qualification for a new four-dose vial version of its Synflorix vaccine for pneumococcal disease in infants and children.

This pre-qualification is mainly for countries that receive support from Gavi, an organisation that seeks to improve access to vaccines for children in, and is aimed at ensuring that vaccines secured through UNICEF for national immunization in low and middle income countries are appropriately safe and effective.

This follows on from a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.

The formulation of the vaccine has been developed to specifically address cold-chain and storage challenges faced in some areas of the world, Glaxo said.

"Today's WHO pre-qualification for our Synflorix four-dose vial is an important step in helping to ensure children under the age of five in developing countries are protected against this deadly disease. Since 2009, we have delivered more than 500 million doses of this critical pneumococcal vaccine. Through this presentation, we are committed to expanding access to children in Gavi countries where the need is greatest," said Glaxo Vaccines Chief Medical Officer Thomas Breuer.

Shares in Glaxo were up 1.0% at 1,531.50 pence Wednesday.

By Hana Stewart-Smith; [email protected]; @HanaSSAllNews

Copyright 2017 Alliance News Limited. All Rights Reserved.